# FOENIX-CCA2 (NCT02052778)

> A Study of TAS-120 in Patients With Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02052778
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Taiho Oncology, Inc.
- Conditions: Cholangiocarcinoma; Urothelial Cancer; Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors; Primary CNS Tumors; Breast Cancer; Gastric Cancer
- Interventions: Futibatinib
- Enrollment: 407
- Primary outcome: Phase 1: Dose Escalation-Maximum Tolerated Dose (MTD)
- Primary outcome: Phase 1: Dose Escalation-Recommended Phase 2 Dose (RP2D) of TAS-120
- Primary outcome: Phase 1: Dose Expansion: Percentage of Participants With Objective Response
- Primary outcome: Phase 2: Percentage of Participants With Objective Response

## Indexed commentary on FOENIX-CCA2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 14
- YouTube: 10
- Podcasts: 9

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=foenix-cca2-nct02052778

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02052778", "email": "<work email>"}; the inbox owner confirms by the emailed link.